Gilder Gagnon Howe & Co. LLC increased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 25.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,189 shares of the biopharmaceutical company’s stock after buying an additional 2,243 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in ACADIA Pharmaceuticals were worth $312,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $145,000. Teachers Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 15.2% in the fourth quarter. Teachers Advisors LLC now owns 122,300 shares of the biopharmaceutical company’s stock worth $3,527,000 after buying an additional 16,099 shares during the last quarter. Winslow Evans & Crocker Inc. boosted its position in shares of ACADIA Pharmaceuticals by 45.7% in the first quarter. Winslow Evans & Crocker Inc. now owns 5,100 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 1,600 shares during the last quarter. Fox Run Management L.L.C. boosted its position in shares of ACADIA Pharmaceuticals by 89.5% in the first quarter. Fox Run Management L.L.C. now owns 21,600 shares of the biopharmaceutical company’s stock worth $743,000 after buying an additional 10,200 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 510 shares during the last quarter. 97.34% of the stock is currently owned by institutional investors.
ACADIA Pharmaceuticals Inc. (ACAD) opened at 30.23 on Friday. ACADIA Pharmaceuticals Inc. has a 52 week low of $20.68 and a 52 week high of $40.83. The firm has a 50-day moving average of $29.28 and a 200 day moving average of $32.02. The firm’s market capitalization is $3.69 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The firm had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. During the same period last year, the company earned ($0.63) earnings per share. The firm’s revenue for the quarter was up 30400.0% on a year-over-year basis. Analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.62) earnings per share for the current year.
A number of brokerages have recently commented on ACAD. ValuEngine raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday. Cowen and Company reaffirmed an “outperform” rating and issued a $46.00 target price (up from $42.00) on shares of ACADIA Pharmaceuticals in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday. Piper Jaffray Companies set a $54.00 target price on shares of ACADIA Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Finally, BidaskClub raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $43.01.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 1,903 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $30.00, for a total value of $57,090.00. Following the sale, the executive vice president now directly owns 83,059 shares of the company’s stock, valued at $2,491,770. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.25% of the stock is owned by company insiders.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.